e.g. mhealth
Search Results (1 to 9 of 9 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 2 JMIR Cardio
- 2 JMIR Medical Informatics
- 2 JMIR Research Protocols
- 1 Interactive Journal of Medical Research
- 1 JMIR Public Health and Surveillance
- 1 JMIRx Bio
- 0 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Formative Research
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
In addition to decreasing low-density lipoprotein (LDL) levels, statins also promote improvement of endothelial function, decrease of platelet aggregation, and reduction of vascular inflammation [12]. LDL levels are used to monitor the intensity of therapy [13-15]. Guideline-directed therapies, including statins have been underused by patients with ACS [16].
JMIR Cardio 2025;9:e58837
Download Citation: END BibTex RIS
Inhibiting HMG-Co A (3-hydroxy-3-methylglutaryl-coenzyme A) reductase (HMGR) is a key therapeutic strategy for managing hypercholesterolemia, with statins serving as the most widely used competitive inhibitors; however, their prolonged use is associated with adverse effects. This study aims to identify novel, natural inhibitors of HMGR as potential alternatives to statins.
JMIRx Bio 2025;3:e74084
Download Citation: END BibTex RIS
International, evidence-based clinical practice guidelines strongly and consistently recommend that adults with CVD, CAD, PAD, and polyvascular disease be prescribed and take antiplatelets and statins (ie, hydroxymethylglutaryl-Co A reductase inhibitors) [7-11]. They also recommend antihypertensives for those patients with concurrent hypertension [7-11].
JMIR Res Protoc 2025;14:e60326
Download Citation: END BibTex RIS
This may explain the response to the television program “Catalyst” in Australia [14], whose criticism of statins resulted in 11% of patients (in a survey by the Australian National Heart Foundation of 1094 patients) who watched the program ceasing to take their cholesterol-lowering medication and significant and sustained changes in statin usage, with 2.6% fewer statins (equivalent to 14,005 dispensing) each week [15].
There is considerable heterogeneity in the quality of web-based health information [16].
Interact J Med Res 2024;13:e42849
Download Citation: END BibTex RIS
As such, people with ACS typically require multiple medications including aspirin, β-blockers, and statins to prevent future cardiac events [4]. Current guidelines recommend the long-term use of 5 classes of medications in secondary prevention following ACS: aspirin, statins, β-blockers, angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and in addition P2 Y12 inhibitors for 1 year to reduce future ACS incidents and associated cardiac complications.
JMIR Cardio 2023;7:e52697
Download Citation: END BibTex RIS
Leveraging National Claims and Hospital Big Data: Cohort Study on a Statin-Drug Interaction Use Case
Indeed, 36.9% [16] of French people aged 34 to 65 years have hypercholesterolemia, and statins are the most prescribed lipid-lowering treatment drugs in France [17]. The current European treatment guidelines [18] recommend statins as the first-choice drug for hypercholesterolemia management. However, 10% to 25% of patients treated with statins experience muscle side effects [19], including rhabdomyolysis (incidence: 1-3 in 100,000 persons per year) [20].
JMIR Med Inform 2021;9(12):e29286
Download Citation: END BibTex RIS
Of the medications associated with lower odds of self-reported typical COVID-19 symptoms, statins showed the most distinct results. Most common symptoms reported by participants using statins were dry cough, sore throat, and headache. In addition, statins were associated with lower odds of fever, joint or muscle pain, and loss of smell or taste. However, the latter associations did not reach statistical significance.
JMIR Public Health Surveill 2020;6(4):e22521
Download Citation: END BibTex RIS
Statins are effective as lipid-lowering drugs and mainly used for the treatment of cardiovascular diseases [68]. Statins are also well known for their anti‐inflammatory effects [69] and some studies have supported the use of these drugs as part of a COVID‐19 treatment protocol [70]. Multiple clinical trials (eg, NCT04343001, NCT04380402) have been launched to determine the efficacy of statins against COVID-19 [71,72].
JMIR Med Inform 2020;8(11):e21648
Download Citation: END BibTex RIS
A number of randomized clinical trials, meta-analyses and cohort studies have demonstrated that long-term administration of aspirin, statins, beta-blockers, and angiotensin-converting enzyme inhibitors (ACEI) or angiotensin-receptor blockers (ARB) improve survival in high-risk patients, particularly those with established CVD. Nevertheless, adherence to prescribed medication is poor for long-term drug treatment in CVD [1,4-6].
JMIR Res Protoc 2018;7(3):e73
Download Citation: END BibTex RIS